Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story?
Monte Rosa Therapeutics announced a past supply agreement with Johnson & Johnson under which Johnson & Johnson will provide ERLEADA (apalutamide) for a Monte Rosa–sponsored Phase 2 trial evaluating MRT-2359 in patients with metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor mutations, with study initiation planned for the third quarter of 2026. This collaboration builds on encouraging e…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
